Committed to innovative surgical solutions

Developing advanced energy-based surgical solutions

Our products improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients.

About Us

We are developing next-generation, advanced surgical solutions

Innoblative, a private medical device company addressing unmet clinical needs for patients with breast cancer and other soft tissue diseases, received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company's SIRA® RFA Electrosurgical Device.

SIRA® is designed specifically for intraoperative coagulation and ablation of soft tissue. A single-use disposable applicator, the SIRA® device is used in conjunction with a radiofrequency electrosurgical generator to effectively ablate target tissue.

SIRA® has received FDA clearance and CE Mark approval. Innoblative has multiple platform devices in development.

SIRA®, a novel breakthrough device targeting the challenges of breast-conserving surgery (BCS):

Radiofrequency ablation is clinically proven to be safe and effective.
Designed for radiofrequency ablation of the post-lumpectomy cavity during breast conserving surgery.
Provides localized margin control to reduce the need for reoperation.

If you are interested in being part of our upcoming clinical trial, contact us here.

Recent Announcements

Join Us At The 25th ASBrS 2024 Annual Meeting

When: April 10–14, 2024
Location: Orlando World Center Marriott, Orlando, FL 32821

Join Us at the Society of Surgical Oncology (SSO) Annual Meeting

When: March 20-23 2024
Location: Georgia World Congress Center, Atlanta, GA 30313

Join Us at NYMBCG 50TH Annual Breast Cancer Symposium

When: March 2, 2024
Location: New York Academy of Medicine (NYAM) New York, NY